JP2018535245A - 化合物の活性化のためのオゾン分解、およびオゾンの分解 - Google Patents

化合物の活性化のためのオゾン分解、およびオゾンの分解 Download PDF

Info

Publication number
JP2018535245A
JP2018535245A JP2018534470A JP2018534470A JP2018535245A JP 2018535245 A JP2018535245 A JP 2018535245A JP 2018534470 A JP2018534470 A JP 2018534470A JP 2018534470 A JP2018534470 A JP 2018534470A JP 2018535245 A JP2018535245 A JP 2018535245A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
ozone
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018534470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535245A5 (enExample
Inventor
デューク、クリストファー
Original Assignee
エアー クロス、インコーポレイテッド
エアー クロス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアー クロス、インコーポレイテッド, エアー クロス、インコーポレイテッド filed Critical エアー クロス、インコーポレイテッド
Publication of JP2018535245A publication Critical patent/JP2018535245A/ja
Publication of JP2018535245A5 publication Critical patent/JP2018535245A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/40—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with ozone; by ozonolysis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34—Chemical or biological purification of waste gases
    • B01D53/46—Removing components of defined structure
    • B01D53/66—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34—Chemical or biological purification of waste gases
    • B01D53/74—General processes for purification of waste gases; Apparatus or devices specially adapted therefor
    • B01D53/77—Liquid phase processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/08—Acetone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/34—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with ozone; by hydrolysis of ozonides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/244—Anthraquinone radicals, e.g. sennosides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2258/00—Sources of waste gases
    • B01D2258/06—Polluted air
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Biochemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
JP2018534470A 2015-09-20 2016-09-19 化合物の活性化のためのオゾン分解、およびオゾンの分解 Pending JP2018535245A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562221030P 2015-09-20 2015-09-20
US62/221,030 2015-09-20
US201562237699P 2015-10-06 2015-10-06
US62/237,699 2015-10-06
PCT/US2016/052529 WO2017049305A1 (en) 2015-09-20 2016-09-19 Ozonolysis for activation of compounds and degradation of ozone

Publications (2)

Publication Number Publication Date
JP2018535245A true JP2018535245A (ja) 2018-11-29
JP2018535245A5 JP2018535245A5 (enExample) 2019-10-31

Family

ID=58289778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534470A Pending JP2018535245A (ja) 2015-09-20 2016-09-19 化合物の活性化のためのオゾン分解、およびオゾンの分解

Country Status (12)

Country Link
US (1) US20210393674A1 (enExample)
EP (1) EP3349893A4 (enExample)
JP (1) JP2018535245A (enExample)
KR (1) KR20180072696A (enExample)
CN (1) CN108348894A (enExample)
AU (1) AU2016324493A1 (enExample)
CA (1) CA2999155A1 (enExample)
MX (1) MX2018003258A (enExample)
PH (1) PH12018550030A1 (enExample)
RU (1) RU2018114529A (enExample)
WO (1) WO2017049305A1 (enExample)
ZA (1) ZA201802498B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3548013A4 (en) * 2016-11-30 2020-11-25 Christopher Duke FREE RADICAL AND REACTIVE OXYGEN SPECIES-REACTIVE COMPOUNDS
EP3720558A1 (en) * 2017-12-07 2020-10-14 Christopher Duke Mitochondria targeting, mptp regulation, and the reduction of mitochondrial reactive species
CN111848606B (zh) * 2019-04-30 2023-03-21 首都医科大学 茶氨酰四氢咪唑并吡啶-6-甲酰甘氨酸和丙氨酸的制备,活性和应用
CN111296417B (zh) * 2020-04-01 2021-04-20 广东省农业科学院植物保护研究所 一种星·甲维悬浮剂及其制备方法与应用
CN114149718B (zh) * 2020-09-08 2023-03-24 三诺生物传感股份有限公司 生物传感器的成膜组合物及其制备方法
CN113582776B (zh) * 2021-08-06 2022-05-31 安徽省司尔特肥业股份有限公司 一种大蒜硫包衣复混肥及其制备方法
CN114307964B (zh) * 2022-01-17 2022-12-20 合肥学院 一种基于废纸箱制备掺杂铁氮生物炭功能材料的方法及应用
CN115025611B (zh) * 2022-07-12 2024-03-29 景德镇富祥生命科技有限公司 一种有效去除子囊霉素发酵尾气异味的方法
CN117695279A (zh) * 2023-11-28 2024-03-15 九华华源药业(桂林)有限公司 氯雷他定组合物及氯雷他定药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2127096A (en) * 1936-02-11 1938-08-16 Gen Aniline Works Inc Polycyclic aromatic aldehydes and carboxylic acids and a process of preparing them
JP2007504244A (ja) * 2003-09-05 2007-03-01 ザ スクリプス リサーチ インスティテュート アテローム硬化症および／または心血管性疾患の処置および予防のためのコレステロールのオゾン化産物
US20070276165A1 (en) * 2006-05-09 2007-11-29 Bernhard Gutsche Process for the ozonolysis of unsaturated compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE97620C (enExample) *
US4336356A (en) * 1978-12-15 1982-06-22 Allied Corporation Production of ozonides from unsaturated polymers
US20030165404A1 (en) 2000-06-05 2003-09-04 Takeshi Omatsu Ozone indicator and method of measuring ozone concentration
AT500489A1 (de) * 2001-03-09 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von mono- oder biscarbonyl- oder hydroxylverbindungen
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
BR0316245A (pt) * 2002-11-14 2005-10-04 Novartis Ag Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
CN1875030A (zh) * 2003-09-05 2006-12-06 斯克里普斯研究学院 用于治疗和预防动脉粥样硬化和/或心血管疾病的胆甾醇臭氧化产物
CN1878787A (zh) * 2003-09-05 2006-12-13 斯克里普斯研究学院 胆甾醇臭氧化产物的检测
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
CA2566180A1 (en) * 2004-05-10 2005-11-24 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of cancer
US8778876B2 (en) * 2011-03-04 2014-07-15 The Board Of Regents Of The University Of Texas System Small-molecule inhibitors of Dengue and West Nile virus proteases
EP2723452A2 (en) * 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
KR20170041849A (ko) * 2014-08-08 2017-04-17 크리스토퍼 듀크 대기 오존 농도 저감용 조성물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2127096A (en) * 1936-02-11 1938-08-16 Gen Aniline Works Inc Polycyclic aromatic aldehydes and carboxylic acids and a process of preparing them
JP2007504244A (ja) * 2003-09-05 2007-03-01 ザ スクリプス リサーチ インスティテュート アテローム硬化症および／または心血管性疾患の処置および予防のためのコレステロールのオゾン化産物
US20070276165A1 (en) * 2006-05-09 2007-11-29 Bernhard Gutsche Process for the ozonolysis of unsaturated compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL REVIEW, vol. 106, JPN6020031805, 2006, pages 2990 - 3001, ISSN: 0004492064 *

Also Published As

Publication number Publication date
RU2018114529A (ru) 2019-10-22
EP3349893A4 (en) 2019-09-11
CN108348894A (zh) 2018-07-31
AU2016324493A1 (en) 2018-05-10
MX2018003258A (es) 2019-02-07
PH12018550030A1 (en) 2018-09-24
US20210393674A1 (en) 2021-12-23
WO2017049305A1 (en) 2017-03-23
ZA201802498B (en) 2023-01-25
KR20180072696A (ko) 2018-06-29
CA2999155A1 (en) 2017-03-23
EP3349893A1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
EP3349893A1 (en) Ozonolysis for activation of compounds and degradation of ozone
JP6929479B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
JP2023509379A (ja) 治療剤の標的化送達のための操作された血小板
US20250213601A1 (en) Methods and bioavailable highly permeable compounds for the treatment of viral diseases
EP1901736B1 (en) Pharmaceutical composition comprising simvastatin and ezetimibe
JP2019203032A (ja) 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
JP2015510818A (ja) 薬物送達のための絹リザーバー
KR102363923B1 (ko) 세기관지염이 있는 유아를 위한 산화질소 흡입 치료
CN106535889A (zh) 用于治疗肺疾病的肥大细胞稳定剂
JP6087827B2 (ja) 可食性フィルムに含まれる用量サイズを分析し確立する方法
JPH09512027A (ja) アモキシリンおよびクラブラン酸塩からなるポリマー被覆錠
US20250041208A1 (en) New injectable combination formulation
JP2024516340A (ja) Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール
CN115916258A (zh) 糖皮质激素减量剂
EP2514422A1 (en) Elution-stabilized preparation
CN116940351A (zh) 前药组合物和治疗方法
WO2025124483A1 (en) Oral drug dosage form for targeted drug delivery based on tracking marker and methods of design and use thereof
HK1256661A1 (en) Ozonolysis for activation of compounds and degradation of ozone
JP2025521240A (ja) 医薬組成物の調製のための気相堆積技術
Shoemark et al. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands binding the Free Fatty Acid Pocket of SARS-CoV-2 Spike Protein
CN121866047A (zh) 药物剂型及其制备方法
WO2024127018A1 (en) New injectable suspension of coated particles
C. Amaral et al. Nanotechnological strategies to improve antifungal therapy
Brož Nanotechnologies for Targeted Delivery of

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210422